Cargando…
Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation
Inhibitors of the mitochondrial respiratory chain complex I are suggested to exert anti-tumor activity on those tumors relying on oxidative metabolism and are therefore of interest to oncology research. Nevertheless, the safety profile of these inhibitors should be thoroughly assessed. Rotenone, a p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379642/ https://www.ncbi.nlm.nih.gov/pubmed/28374803 http://dx.doi.org/10.1038/srep45465 |
_version_ | 1782519645971939328 |
---|---|
author | Heinz, Sabrina Freyberger, Alexius Lawrenz, Bettina Schladt, Ludwig Schmuck, Gabriele Ellinger-Ziegelbauer, Heidrun |
author_facet | Heinz, Sabrina Freyberger, Alexius Lawrenz, Bettina Schladt, Ludwig Schmuck, Gabriele Ellinger-Ziegelbauer, Heidrun |
author_sort | Heinz, Sabrina |
collection | PubMed |
description | Inhibitors of the mitochondrial respiratory chain complex I are suggested to exert anti-tumor activity on those tumors relying on oxidative metabolism and are therefore of interest to oncology research. Nevertheless, the safety profile of these inhibitors should be thoroughly assessed. Rotenone, a proven complex I inhibitor, has shown anti-carcinogenic activity in several studies. In this context rotenone was used in this study as a tool compound with the aim to identify suitable biomarker candidates and provide enhanced mechanistic insights into the molecular and cellular effects of complex I inhibitors. Rats were treated with 400 ppm rotenone daily for 1, 3 or 14 consecutive days followed by necropsy. Classical clinical endpoints, including hematology, clinical chemistry and histopathology with supporting investigations (FACS-analysis, enzymatic activity assays) were examined as well as gene expression analysis. Through these investigations, we identified liver, bone marrow and bone as target organs amongst approx. 40 organs evaluated at least histopathologically. Our results suggest blood analysis, bone marrow parameters, assessment of lactate in serum and glycogen in liver, and especially gene expression analysis in liver as useful parameters for an experimental model to help to characterize the profile of complex I inhibitors with respect to a tolerable risk-benefit balance. |
format | Online Article Text |
id | pubmed-5379642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53796422017-04-07 Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation Heinz, Sabrina Freyberger, Alexius Lawrenz, Bettina Schladt, Ludwig Schmuck, Gabriele Ellinger-Ziegelbauer, Heidrun Sci Rep Article Inhibitors of the mitochondrial respiratory chain complex I are suggested to exert anti-tumor activity on those tumors relying on oxidative metabolism and are therefore of interest to oncology research. Nevertheless, the safety profile of these inhibitors should be thoroughly assessed. Rotenone, a proven complex I inhibitor, has shown anti-carcinogenic activity in several studies. In this context rotenone was used in this study as a tool compound with the aim to identify suitable biomarker candidates and provide enhanced mechanistic insights into the molecular and cellular effects of complex I inhibitors. Rats were treated with 400 ppm rotenone daily for 1, 3 or 14 consecutive days followed by necropsy. Classical clinical endpoints, including hematology, clinical chemistry and histopathology with supporting investigations (FACS-analysis, enzymatic activity assays) were examined as well as gene expression analysis. Through these investigations, we identified liver, bone marrow and bone as target organs amongst approx. 40 organs evaluated at least histopathologically. Our results suggest blood analysis, bone marrow parameters, assessment of lactate in serum and glycogen in liver, and especially gene expression analysis in liver as useful parameters for an experimental model to help to characterize the profile of complex I inhibitors with respect to a tolerable risk-benefit balance. Nature Publishing Group 2017-04-04 /pmc/articles/PMC5379642/ /pubmed/28374803 http://dx.doi.org/10.1038/srep45465 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Heinz, Sabrina Freyberger, Alexius Lawrenz, Bettina Schladt, Ludwig Schmuck, Gabriele Ellinger-Ziegelbauer, Heidrun Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title | Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title_full | Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title_fullStr | Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title_full_unstemmed | Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title_short | Mechanistic Investigations of the Mitochondrial Complex I Inhibitor Rotenone in the Context of Pharmacological and Safety Evaluation |
title_sort | mechanistic investigations of the mitochondrial complex i inhibitor rotenone in the context of pharmacological and safety evaluation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379642/ https://www.ncbi.nlm.nih.gov/pubmed/28374803 http://dx.doi.org/10.1038/srep45465 |
work_keys_str_mv | AT heinzsabrina mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation AT freybergeralexius mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation AT lawrenzbettina mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation AT schladtludwig mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation AT schmuckgabriele mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation AT ellingerziegelbauerheidrun mechanisticinvestigationsofthemitochondrialcomplexiinhibitorrotenoneinthecontextofpharmacologicalandsafetyevaluation |